Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Liquid Biopsy For Cancer Diagnostics Market Growth From $12.52 Billion In 2026 To $22.99 Billion By 2030 At A CAGR Of 16.4%
The liquid biopsy for cancer diagnostics market size has experienced swift expansion in recent years. This market is projected to expand from $10.75 billion in 2025 to reach $12.52 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 16.4%. Historically, this expansion can be ascribed to factors such as the limitations of tissue biopsy procedures, the increasing incidence of lung and breast cancer, the early adoption of molecular cancer diagnostics, the growing need for early-stage cancer detection, and rising clinical research in oncology diagnostics.
The liquid biopsy for cancer diagnostics market size is projected to experience substantial expansion over the upcoming years. By 2030, this market is anticipated to reach $22.99 billion, demonstrating a compound annual growth rate (CAGR) of 16.4%. Several factors are driving this anticipated growth, including the broader application of liquid biopsy in routine cancer screening, an increased emphasis on tailored cancer care, its growing acceptance for monitoring treatment responses, escalating investments in cancer diagnostics, and its expanded utility in addressing gastrointestinal and ovarian cancers. Key trends expected during the forecast period involve the increasing integration of liquid biopsy for diagnosing lung cancer, a surge in the use of blood-based screening techniques for cancer, a heightened need for continuous cancer monitoring, the extension of liquid biopsy applications to various cancer forms, and a growing clinical inclination towards less invasive diagnostic approaches.
Get A Free Sample Report With In-Depth Market Insights:
Liquid Biopsy For Cancer Diagnostics Market Growth Backed By Core Demand Fundamentals
The increasing prevalence of cancer is anticipated to fuel the expansion of the liquid biopsy for cancer diagnostics market in the coming years. Cancer is characterized as a wide range of diseases that can arise in almost any organ or tissue in the body when abnormal cells multiply uncontrollably, breach their typical borders, and spread to other organs or invade nearby tissues. The presence of cancer necessitates diagnostic processes like identifying early cancer or tumor recurrence, evaluating patient-specific risks, and overseeing treatment. This makes liquid biopsy particularly valuable, as it can illustrate the comprehensive nature of the disease by detecting tumor cells or their products released from all primary or metastatic tumor sites, thereby offering detailed and real-time insights into tumor cell changes, therapeutic targets, and how tumors resist treatment. For example, in May 2024, data from the National Cancer Institute, a US-based government agency, indicated approximately 18.1 million cancer survivors in the United States. This number is predicted to grow to 22.5 million by 2032. Furthermore, by 2040, the annual count of new cancer diagnoses is expected to hit 29.9 million, with cancer-related fatalities projected to climb to 15.3 million. Consequently, the escalating incidence of cancer is a key factor propelling the development of the liquid biopsy for cancer diagnostics market.
Liquid Biopsy For Cancer Diagnostics Market Segment Trends And Revenue Contributors
The liquid biopsy for cancer diagnostics market covered in this report is segmented –
1) By Type: Product, Services
2) By Sample: Blood, Urine, Saliva
3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers
4) By End-User: Hospitals, Diagnostic Centers, Other End-Users
Subsegments:
1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices
2) By Services: Testing Services, Analytical Services, Bioinformatics Services
Liquid Biopsy For Cancer Diagnostics Market Growth Trends Reshaping The Competitive Landscape
Companies active in the liquid biopsy for cancer diagnostics market are concentrating their efforts on creating innovative solutions, such as advanced liquid biopsy assays. An advanced liquid biopsy assay denotes a sophisticated and highly refined diagnostic test that examines various components present in a liquid biological sample, like blood or other bodily fluids, to detect and characterize specific biomarkers associated with cancer or other diseases. For instance, in November 2023, Illumina Inc., a US-based global leader in DNA sequencing, announced the introduction of ‘TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2)’. This is a research assay engineered to facilitate noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) obtained from blood. The TSO 500 ctDNA v2 assay is designed to simplify integration for users and enhance the depth of insights available for cancer research.
Liquid Biopsy For Cancer Diagnostics Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the liquid biopsy for cancer diagnostics market are F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC
View The Full Liquid Biopsy For Cancer Diagnostics Market Report:
Liquid Biopsy For Cancer Diagnostics Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the liquid biopsy for cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
